Accrued liabilities consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
(in thousands) |
|
2025 |
|
|
2024 |
|
Accrued compensation |
|
$ |
6,948 |
|
|
$ |
13,305 |
|
Cystic Fibrosis Foundation liability |
|
|
6,394 |
|
|
|
7,443 |
|
Current portion of operating lease liability |
|
|
4,214 |
|
|
|
3,552 |
|
Accrued facilities costs |
|
|
1,400 |
|
|
|
— |
|
Clinical trial accruals |
|
|
399 |
|
|
|
2,828 |
|
Vinbiocare contractual liabilities |
|
|
— |
|
|
|
2,421 |
|
Legal accrual |
|
|
771 |
|
|
|
130 |
|
Other accrued research and development expenses |
|
|
3,772 |
|
|
|
9,102 |
|
Total |
|
$ |
23,898 |
|
|
$ |
38,781 |
|
|